Evidence map›Paper›PMID 22272219›Full record

ArticleTheranostics2012

Magnetic Nanoparticles and microNMR for Diagnostic Applications.

Huilin Shao, Changwook Min, David Issadore, Monty Liong, Tae-Jong Yoon, Ralph Weissleder, Hakho Lee

Abstract read
In one paragraph

Article in Theranostics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Review
  2. Magnetic nanoparticles for cancer theranostics.Biomedical physics & engineering express · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. The emerging role of extracellular vesicles in retinal diseases.American journal of translational research · 2021
    Review
  12. Article
  13. Article
  14. Magnetic Nanoparticles in Cancer Therapy and Diagnosis.Advanced healthcare materials · 2020
    Review
  15. Review
  16. Article
  17. Biosensors for Detection of Human Placental Pathologies: A Review of Emerging Technologies and Current Trends.Translational research : the journal of laboratory and clinical medicine · 2019
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huilin Shao1. Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114;
Changwook Min
David Issadore
Monty Liong
Tae-Jong Yoon
Ralph Weissleder
Hakho Lee

Funding

TREATMENT OF CANCER WITH siRNA DELVIERED BY NANOPARTICLESU54CA119349 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2005 to 2009
$20.5M
Translational Program of Excellence in NanotechnologyU01HL080731 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2005 to 2009
$14.9M
Training Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1M
Magnetic nanoswitches for sensing biomoleculesR01EB004626 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2004 to 2012
$3.2M
NCI NIH HHS T32 CA079443NCI NIH HHS U54 CA119349NHLBI NIH HHS HHSN268201000044CNHLBI NIH HHS U01 HL080731NIBIB NIH HHS R01 EB004626
6 · The paper itself

Abstract

Sensitive and quantitative measurements of clinically relevant protein biomarkers, pathogens and cells in biological samples would be invaluable for disease diagnosis, monitoring of malignancy, and for evaluating therapy efficacy. Biosensing strategies using magnetic nanoparticles (MNPs) have recently received considerable attention, since they offer unique advantages over traditional detection methods. Specifically, because biological samples have negligible magnetic background, MNPs can be used to obtain highly sensitive measurements in minimally processed samples. This review focuses on the use of MNPs for in vitro detection of cellular biomarkers based on nuclear magnetic resonance (NMR) effects. This detection platform, termed diagnostic magnetic resonance (DMR), exploits MNPs as proximity sensors to modulate the spin-spin relaxation time of water molecules surrounding the molecularly-targeted nanoparticles. With new developments such as more effective MNP biosensors, advanced conjugational strategies, and highly sensitive miniaturized NMR systems, the DMR detection capabilities have been considerably improved. These developments have also enabled parallel and rapid measurements from small sample volumes and on a wide range of targets, including whole cells, proteins, DNA/mRNA, metabolites, drugs, viruses and bacteria. The DMR platform thus makes a robust and easy-to-use sensor system with broad applications in biomedicine, as well as clinical utility in point-of-care settings.

Indexed as

biosensordiagnosticsmagnetic nanoparticlemicrofluidicsnuclear magnetic resonance.

Identifiers

PMID22272219
PMCPMC3263516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.